Document:

Exhibit 4.29

  
 COMPONENT MANUFACTURING AGREEMENT
 This Component Manufacturing Agreement (the “Agreement”) is made and entered into as of April 3, 2017 (the “Effective Date”) by and between:
 MICROPORT ENDOVASCULAR (SHANGHAI) CO., LTD., a company organized and existing under the laws of People’s Republic of China, whose registered office is at Building 1, Lane 3399, Kangxin Road, Pudong New District, Shanghai, 201318 P. R. China (the “MICROPORT”), and
 LOMBARD MEDICAL LIMITED., a Company organized and existing under the laws of England with registered offices in Lombard Medical House, 4 Trident Park, Didcot, Oxfordshire, OX11 7HJ, United Kingdom (the “LOMBARD”). 
 MICROPORT and LOMBARD may be referred to herein as a “Party” or, collectively, as the “Parties.”
 RECITALS:
 WHEREAS, in connection with the investment in and strategic collaboration between LOMBARD and MICROPORT SCIENTIFIC CORPORATION.
 WHEREAS, the Parties acknowledge that a key element for the strategic collaboration is to reduce the cost of manufacturing for Products (as defined below).  
 WHEREAS, during the term of this Agreement, LOMBARD wishes to engage MICROPORT to manufacture and supply the Components (as defined below) of Products to support the manufacturing of Products in accordance with the terms and conditions of this Agreement.
 NOW, THEREFORE, in consideration of their mutual covenants and agreements contained herein, and the mutual benefits to be derived here from, the Parties, intending to be legally bound, hereby covenant and agree as follows:
 COVENANTS:
 Article 1
DEFINITIONS
 1.01          Capitalized terms in this Agreement shall have the following meanings:
  “Affiliate” shall mean, with respect to any Person, any other Person which controls, is controlled by, or is under common control with such Person.  A Person shall be regarded as in control of another entity if it owns or controls more than fifty percent (50%) of the equity securities of the subject entity entitled to vote in the election of directors (or, in the case of an entity that is not a corporation, for the election of the corresponding managing authority).  Notwithstanding the foregoing, with respect to a Party, “Affiliate” does not include a purchaser or holder of such Party’s equity securities that acquired or acquires such equity securities solely for investment purposes such as a venture capital fund or private equity fund.
 1
  
 
  
  
 “Agreement” shall mean this Component Manufacturing Agreement, including the Exhibits attached hereto, as such may be amended from time to time.
 “Applicable Law” shall mean all applicable provisions of all statutes, laws, rules, regulations, administrative codes, ordinances, decrees, orders, decisions, injunctions, awards judgments, permits and licenses of or from Governmental Authorities.
 “Bankruptcy Event” shall mean the Person in question becomes insolvent, or voluntary or involuntary proceedings by or against such person or entity are instituted in bankruptcy or under any insolvency law, or a receiver or custodian is appointed for such person or entity, or proceedings are instituted by or against such person or entity for corporate reorganization or the dissolution of such person or entity, which proceedings, if involuntary, shall not have been dismissed within sixty (60) days after the date of filing, or such person or entity makes an assignment for the benefit of its creditors, or substantially all of the assets of such person or entity are seized or attached and not released within sixty (60) days thereafter.
  “Business Day(s)” shall mean Monday through Friday, and shall exclude Saturday, Sunday, and public holidays in P.R China.
 “Change of  Control ” shall mean with respect to a Party, a change in ownership or control of such Party effected through (i) the acquisition, directly or indirectly, by any Person or related group of Persons different from the persons holding those securities immediately prior to such transaction, of beneficial ownership of securities possessing fifty percent (50%) or more of the total combined voting power of such Party’s outstanding securities, (ii) a merger or consolidation in which securities possessing fifty percent (50%) or more of the total combined voting power of such Party’s outstanding securities are transferred to a Person or Persons different from the persons holding those securities immediately prior to such transaction; or (iii) the sale, transfer, exclusive license or other disposition of all or substantially all of such Party’s assets, or any material technology or intellectual property of such Party; provided, however, that any internal restructuring, reorganizing, or event where the existing shareholders retain control, shall not constitute a Change of Control for the purposes of this Agreement.
 “Component(s)” shall mean any and all of the components agreed by both Parties for the manufacturing of the Products. Components listed in Exhibit A may be changed, deleted or added by the mutual consent in writing of Parties.
 “Effective Date” shall mean the date of execution of this Agreement; 
 “FDA” shall mean the United States Department of Health and Human Services Food and Drug Administration or any successor agency.
 “Facility” shall mean MICROPORT’s manufacturing facility or facilities in China otherwise noticed in advance.
 “Force Majeure Event” shall mean any event beyond the reasonable control of the Party affected by such event and which occurs without the fault or negligence of such Party or any of its subcontractors or suppliers, including, but not limited to, an act of God, delay or loss in transportation, fire, flood, earthquake, storm, war, riot, revolt, act of a public enemy, embargo, explosion, civil commotion, strike, act of terror, labor dispute, loss or shortage of power, impossibility or delay of obtaining raw materials or shortage in supply of raw materials or any law, rule, regulation, order by any Governmental Authority except for any action regarding public policy.  In each instance, the failure to perform must be beyond the reasonable control of the first Party.  
 2
  
 
  
  
 “GMP” means the part of quality assurance which ensures Components are consistently produced and controlled in accordance with the quality standards appropriate for their intended use. 
 “Governmental Authority” shall mean any court or any governmental or other administrative or regulatory body, authority, department, ministry, agency, tribunal, or commission in the Territory including CFDA (China Food and Drug Administration).
  “Intellectual Property” shall mean any and all trade secrets, patents, copyrights, trademarks, service marks, trade names, domain names, trade dress, URLs, brand features, know- how and similar rights of any type under the laws of any applicable Governmental Authority relating to the Components and Products.
  “Person” shall mean any natural person, corporation, firm, business trust, joint venture, association, organization, company, partnership or other business entity, or any government, or any agency or political subdivisions thereof.
 “Product(s)” shall mean the vascular devices (including stents and delivery system of different specifications) developed by LOMBARD for abdominal aortic aneurysm repair, i.e. AlturaTM and AorfixTM as their trade names. Products may be changed, deleted or added by the mutual consent in writing of Parties. 
 “Purchase Order” shall mean the written instruction of LOMBARD to MICROPORT to manufacture Components set forth in the order.
 “Representative” shall mean, with respect to any Party, any officer, director, principal, attorney, agent, employee or other representative of such Party. 
 “Specifications” shall mean the design and quality specifications of the Components, which shall be provided by LOMBARD prior to manufacture, as such may from time to time be amended by written agreement of the Parties.  “Technical Information” shall mean all the technical and other information developed by LOMBARD and/ or its licensors required for the manufacturing of the Components including without limitation DHF (Design History File), DMR (Device Master Record) ,SOP (Standard Operating Procedure), BOM (Bill of Material) and Specifications, video of manufacturing process, existing supplier information etc.
 “Territory” shall mean the countries, geographical regions, territories globally.
 “Third Party” shall mean any individual or entity other than a Party or an Affiliate of a Party.
 “Work in Process” shall mean partially completed goods, parts, assemblies and/or subassemblies that are no longer part of the raw materials inventory and are not yet a part of the finished Components inventory.  For purposes of this Agreement, the cost of Work in Process shall be all costs incurred by MICROPORT for work in process to complete firm Purchase Orders, including, but not limited to, raw materials, machining time, quality assurance and engineering requirements, specialized tooling and outside subcontractors and vendors.
  
 3
  
 
  
Article 2
AGREEMENT TO COMPONENTS MANUFACTURING 
 2.01          During the term of this Agreement, LOMBARD shall purchase, and MICROPORT shall manufacture and supply to LOMBARD, all Components ordered by LOMBARD, all subject to and in accordance with the terms and conditions of this Agreement.
 2.02          MICROPORT and LOMBARD shall maintain registrations, certifications and licenses as required by Applicable Law for their respective duties.
 2.03          LOMBARD hereby agrees to disclose to MICROPORT its Technical Information relating to the manufacture of Components under this Agreement.
 2.04          LOMBARD hereby agrees to provide to MICROPORT a complete set of tools, machines and equipment necessary for manufacturing of Components under this agreement, in order to facilitate MICROPORT’s establishment of the manufacturing line. The scope of such tools, machines and equipment shall be negotiated and agreed by the Parties.
 Article 3
REGULATORY AND QUALITY REQUIREMENTS
 3.01          Regulatory Approval.  MICROPORT shall be responsible for all Chinese regulatory obligations related to manufacturing of the Components, including all activities related to obtaining Regulatory Approval and maintaining compliance with all applicable regulations related to the Components, such as obtaining the permits and licenses required to be obtained by MICROPORT as required for manufacturing of medical devices for products similar to the Components and its facility (collectively, “MICROPORT Permits”),  MICROPORT shall keep LOMBARD informed as to any material developments with respect to such clinical and regulatory matters which would alter LOMBARD’s obligations under this Agreement.  LOMBARD shall reasonably cooperate with MICROPORT’s regulatory activities in China including providing all data, information and materials within its possession relevant to MICROPORT’s regulatory activities and submitting to required inspections by the relevant regulatory authorities.
 3.02          Quality Systems Requirements.  MICROPORT will maintain a quality system which satisfies LOMBARD’s existing manufacturing processes with other vendors and/or subcontractors and will be in compliance with regulations of FDA, CFDA and/or ISO 13485 standards (where applicable) , remaining subject to periodic audit by LOMBARD. In the event that these regulations are modified, amended, or otherwise updated, MICROPORT will modify, amend, or otherwise update and maintain a quality system in accordance therewith.  
 3.03          Purchasing Records.  LOMBARD shall maintain purchasing records to facilitate tracing of its disposition of Components in accordance with applicable regulatory obligations.  MICROPORT shall maintain records that track Components from the source of materials to shipment to LOMBARD.
 4
  
 
  
  
 3.04          Product Complaints and Adverse Events.  LOMBARD will be the designated Party to receive complaints and will promptly advise MICROPORT, in writing, of complaints that it receives that are attributable to the Components manufactured by MICROPORT.  LOMBARD will maintain, for the period of time required by Applicable Law, product complaint files related to the Components manufactured by MICROPORT under this Agreement including related investigations.  For the avoidance of doubt, (a) LOMBARD will have the ultimate decision-making and approval authority with respect to the handling of all complaints and the taking of investigations and any required corrective actions with respect to the Components and (b) MICROPORT will assist in handling complaints relating to Components manufactured by MICROPORT.
 3.05          Investigations.  MICROPORT will assist in product complaint investigations related to the manufacturing and supplying of Components upon reasonable request from LOMBARD.  
 3.06          Quality Agreement.  The Parties shall enter into a mutually agreed Quality Agreement that satisfies required regulatory requirements prior to the commencement of manufacturing under this Agreement.
 Article 4
MANUFACTURING AND SUPPLY
 4.01          Contact Person.  As soon as reasonably practicable after the Effective Date, each Party shall identify, by written notice, a contact person to serve as the primary liaison between the Parties with regard to manufacturing and supply issues. Each Party may replace its contact person, at any time, upon written notice to the other Party identifying the new contact person.
 4.02          Specifications.  MICROPORT agrees to manufacture and supply Components to LOMBARD in accordance with the Specifications and in compliance with Applicable Law.  The Parties agree to negotiate with each other in good faith in order to make any and all changes to the Specifications that may reasonably be requested by either of the Parties or may be required by any Governmental Authority; provided, however, that it is acknowledged that the price of such Components may change depending on cost impact of those changes to the  Specifications.  LOMBARD agrees to provide MICROPORT with notice ninety (90) days in advance of any changes to the Specifications. In any case, LOMBARD shall remain obliged to purchase Components that are subject to any valid Purchase Order(s). If any such changes cause MICROPORT to incur extra costs and/or expenses, MICROPORT will notify LOMBARD of such extra costs and/or expenses, promptly, and MICROPORT will not implement any such changes until LOMBARD and MICROPORT have come to an agreement that would allow MICROPORT to be reimbursed for such extra costs and/or expenses. Furthermore, if LOMBARD proposes to make any changes to Specifications unilaterally which leads to the redundant and inactive stock of Work in Process, LOMBARD shall compensate MICROPORT the cost of the concerned Work in Process and raw materials according to the invoice issued by MICROPORT. 
 5
  
 
  
  
 4.03          Order and Acceptance of the Component.  The following provisions shall apply to all Purchase Orders hereunder:  
 (a)                No later than one hundred twenty (120) days prior to LOMBARD desiring supply of the first Component under this Agreement to commence, LOMBARD shall deliver to MICROPORT a forecast of its requirements of Components for the succeeding twelve (12) months (the “Initial Production Forecast”).  Thereafter, on or prior to the fifteenth (15th) calendar day of each month during the term of this Agreement, LOMBARD shall deliver to MICROPORT an updated rolling forecast of its requirements of Components for the succeeding twelve (12) months (each such forecast, including the Initial Production Forecast, a “LOMBARD Production Forecast”).  The forecast quantities in each LOMBARD Production Forecast shall be a good faith estimate of the Components expected to be required during such months but shall be non-binding.  However, LOMBARD may not change the first month of any LOMBARD Production Forecast without MICROPORT’s consent.  MICROPORT shall notify LOMBARD within ten (10) Business Days if at any time MICROPORT has reason to believe that it may not be able to satisfy the requirements of Components set forth in a LOMBARD Production Forecast, including in the event that MICROPORT believes that there may be constraints in the supply of raw material components of the Components provided by Third Parties.
 (b)               All Purchase Orders for Components that comply with the most recent LOMBARD Production Forecast shall be filled by MICROPORT so long as there has not been a Force Majeure Event that occurred and is continuing.  Purchase Orders shall specify the Component(s), quantity, Specifications, expected delivery date, packing requirement and price. MICROPORT shall, within two (2) days of receipt of a Purchase Order confirm (by notice in writing) acceptance or rejection of the said Purchase Order. MICROPORT will meet LOMBARD’s delivery requirements as requested (which requirements, in any such event, will be based upon a reasonable evaluation of the relevant Specifications of the applicable Purchase Order mutually agreed by the Parties).  In the event that a Purchase Order for a particular month pursuant to Purchase Orders for a Component are in excess of 100% of the most recent LOMBARD Production Forecast for such Component for such month, then MICROPORT’s obligation will be to fill 100% of the forecasted quantity for such Component for such month and use commercially reasonable efforts to fill the excess part of the Purchase Order.  
 (c)                Minimum Purchase Volume Commitment. LOMBARD shall purchase from MICROPORT a minimum volume of Components each calendar year (“Minimum Purchase Volume”) during the term of this Agreement. At least sixty (60) days prior to the commencement of each calendar year, the Parties shall determine through negotiation in good faith the Minimum Purchase Volume for each Component. 
 4.04          Delivery terms shall be FCA at Shanghai Pudong International Airport (as defined in Incoterms 2010), and LOMBARD shall pay all costs and expenses of shipping to LOMBARD’s facility. Risk in the Components  shall pass to LOMBARD on delivery and title to the Components shall pass to LOMBARD on payment in full of the amount invoiced to LOMBARD. Finished Components shall be packed in accordance with the packing requirements, which must be provided by LOMBARD in advance.
 6
  
 
  
  
 4.05          Inspection of Delivery Upon receipt of each delivery of Components, LOMBARD shall promptly inspect the quantity and package of the delivered Components. LOMBARD shall inform MICROPORT in writing of any shortage or non-satisfaction of packing requirements in a valid Purchase Order. 
 4.06          Reservation of Rights.  Except as expressly provided in this Agreement, or otherwise necessary to carry out the provisions of this Agreement, no right, title or interest is granted, whether express or implied, by either Party to the other, and nothing in this Agreement shall be deemed to restrict each Party’s right to exploit such Party’s own Intellectual Property. Notwithstanding the above, LOMBARD shall remain the sole owner of the Intellectual Property to the Products and the performance of this Agreement shall not be deemed to include a transfer of Intellectual Property of LOMBARD.
 4.07          LOMBARD Intellectual Property Commitment.  As may be required for the fulfilment of this Agreement, for the duration of this Agreement, Lombard will provide licenses to MicroPort to Lombard’s intellectual property that permit the manufacture of patented components by MicroPort.  The licenses will not carry the automatic right to sub-license. LOMBARD hereby represents, covenants and warrants that the requirements and Specifications of Components delivered to MICROPORT shall not infringe the rights of Intellectual Property of Third party, including, without limitation the rights of patents, copyrights, trademarks, service marks, trade names, domain names, trade dress, URLs, brand features, know- how and similar rights of any type under the laws of any applicable Governmental Authority relating to the Components. 
 4.08          Security of Infringement. If MICROPORT is involved in any claim, action, suit, proceeding or investigation asserted by a Third Party or the Components are restricted by customs or Governmental Authority for infringement of Intellectual Property of any Third Party (“Third Party IP Claim”), LOMBARD shall undertake the defense, compromise or settlement of such Third Party IP Claim within thirty (30) days from being notified by MICROPORT, including, without limitation: (a) construing to MICROPORT and assisting MICROPORT to solve the above Third Party IP Claim; and (b) providing the original copies to customs or Governmental Authority for non-infringement evidences. If the construing and original copies shall not protect MICROPORT against the Third Party IP Claim, LOMBARD shall pay the deposits to customs or Governmental Authority as required by MICROPORT. If MICROPORT undertakes the defense jointly with LOMBARD, LOMBARD shall indemnify and hold harmless MICROPORT from and against any and all losses, damages, liabilities, obligations, sanctions, penalties, judgments, awards, costs, expenses, including reasonable attorney and court costs, and disbursements, including without limitation, the costs, expenses and disbursements arising out of such Third Party IP Claim.
 Article 5
DISCLOSURE OF TECHNICAL INFORMATION AND ASSISTANCE
 5.01          LOMBARD shall within a reasonable time after the Effective Date, disclose to MICROPORT the Technical Information, including but without limitation to, drawings, Specifications, videos of manufacturing process, SOPs, BOM(bill of ,materials), existing supplier information, DHF and DMR of the Components and to this end shall provide MICROPORT with copies of all documentary records which record or otherwise relate to the Technical Information to the extent MICROPORT reasonably considers necessary for the manufacture of the Components. 
 7
  
 
  
  
 5.02          MICROPORT acknowledges that the copyright in any documentation supplied by LOMBARD as part of the Technical Information, and all copies of such documentation, shall belong to and remain vested in LOMBARD. MICROPORT shall be permitted to make only such copies of the Technical Information and documentation as are necessary for MICROPORT’s performance of its obligations under this Agreement and understands and acknowledges that all such Technical Information, documentation and copies of the same are subject to the confidentiality obligations. 
 5.03          For the avoidance of doubt, any ownership to any Intellectual Property Rights arising from or relating to manufacturing methods and/or processes used in manufacture of Components hereunder shall be vested in MICROPORT.
 5.04          LOMBARD shall from time to time, at its cost send engineering staff to MICROPORT’s facilities to provide MICROPORT with such reasonable training, advice and assistance as LOMBARD reasonably considers necessary to facilitate MICROPORT’s performance of its obligations under this Agreement. Certificate shall be issued by LOMBARD to personnel of MICROPORT who is qualified for production operation after necessary training.
 Article 6
PRICE AND PAYMENT
 6.01          Prices.  The price for each Component shall be negotiated by Parties and be set forth in Exhibit A before any Purchase Order is issued by LOMBARD.  The prices for the Components shall be in USD and shall be exclusive of VAT and all other applicable taxes and duties. At least sixty (60) days prior to the commencement of each calendar year, the Parties shall determine through negotiation in good faith the price for each Component. Without prejudice to this Section 6.01, prices for the Components can be revised through negotiation in good faith by the Parties in the cases that the costs of the manufacturing increase substantially due to reasons that are not controlled by the Parties
 6.02          Invoice.  MICROPORT shall submit an aggregate invoice to LOMBARD consisting of the invoice prices for the Components delivered within ten (10) days after delivery of such Components.  
 6.03          Payment Terms.  Payment terms will be net sixty  (60) days after the date of the invoice.  Payment of all amounts shall be in U.S. Dollars, by wire transfer of immediately available funds to the financial institution, account number and account party’s name designated in writing by MICROPORT as the place of payment.  
 6.04          Taxes.  All payments required to be made by LOMBARD to MICROPORT under this Agreement are exclusive of any applicable federal, state and local taxes excluding income taxes, value added taxes and gross receipt taxes.  Any present or future sales, revenue, excise, withholding or other tax, fees, or charge of any nature, imposed by any public authority, and applicable to the purchase of Components hereunder (other than value added taxes, gross receipt taxes or taxes based on MICROPORT’s net income) shall be added to the purchase price and shall be paid by LOMBARD unless an exemption therefrom is obtained.
 8
  
 
  

 Article 7
TERM AND TERMINATION
 7.01          Term. This Agreement shall begin on the Effective Date and shall remain in force for five (5) years from the date of the first delivery of Components under this Agreement.
 7.02          Termination for Cause or Upon Bankruptcy.  A Party may terminate this Agreement immediately upon written notice to the other Party as follows:
 (a)                by a Party, effective immediately, in the event that the other Party should commits a material breach of any term of this Agreement and (if that breach is remediable) fails to remedy that breach within thirty (30) days of that Party being required in writing to do so;
 (b)               by a Party, effective immediately, if any Force Majeure Event occurs to the other Party and such event delays or prevents the performance of any obligation under this Agreement by the Party suffering the Force Majeure Event for a period of ninety (90) days or longer; or
 (c)                by a Party, effective immediately, if the other Party should experience a Bankruptcy Event.
 (d)               by a Party, effective immediately, if Change of Control occurs in the other Party.
 7.03          Upon Termination.  Upon termination of this Agreement, LOMBARD’s obligation to MICROPORT shall be: 
 (a)                Payment for and acceptance of delivery for all Components ordered; and
 (b)               Payment for all associated Work-in-Progress, finished goods, specific raw material, including all non-cancelable/non-returnable materials ordered by MICROPORT to full fill LOMBARD’s Purchase Orders.
 7.04          Article 1, Article 8, and Sections 3.03, 3.04, 3.05, 4.06, 4.07, 5.04 7.03 will survive expiration or termination of this Agreement for any reason in accordance with their respective terms 
  9
  
 
  
 
Article 8
REPRESENTATIONS AND WARRANTIES AND INDEMNIFICATION
 8.01          Mutual.  Each Party hereby represents, covenants and warrants to the other Party that:
 (a)                it has the power and authority to enter into this Agreement and to grant the rights and licenses granted herein and otherwise perform this Agreement;
 (b)               to the best of each Party’s knowledge, the entering into of this Agreement by such Party will not (i) violate any provision of law, statute, rule or regulation or any ruling, writ, injunction, order, judgment or decree of any court, administrative agency or other governmental body or (ii) conflict with or result in any breach of any of the terms, conditions or provisions of, or constitute a default under its organizational documents, as amended to date, or any material note, indenture, mortgage, lease, agreement, contract, purchase order or other instrument, document or agreement;
 (c)                when executed and delivered by it, this Agreement will constitute a legal, valid and binding obligation of it, enforceable against it in accordance with the provisions of this Agreement; and
 (d)               it shall perform its obligations under this Agreement in compliance with all Applicable Law.
 8.02          Product Warranty.  MICROPORT warrants that the Component shall be manufactured in accordance with the Specifications provided by LOMBARD and shall be free from defects in materials and workmanship. For the avoidance of doubt, MICROPORT has no liability for any Component that is altered, mishandled or damaged after delivery to Lombard’s facility in Didcot, UK.
 8.03          In the event that Components do not conform to the warranties set forth at Clause 8.02, MICROPORT shall repair or replace and return, (or credit by agreement), including the costs of transportation of such Components at the earliest opportunity after the same.
 8.04          Disclaimer of Other Warranties by MICROPORT.  EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, MICROPORT HEREBY DISCLAIMS ALL REPRESENTATIONS AND WARRANTIES, EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO THE COMPONENTS, INCLUDING, BUT NOT LIMITED TO, ANY IMPLIED WARRANTIES ON DESIGN, PERFORMANCE, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NON-INFRINGEMENT OF INTELLECTUAL PROPERTY RIGHT OF ANY THIRD PARTY.
 8.05          Indemnification.  
 (a)                MICROPORT shall defend, indemnify and hold harmless , and at LOMBARD’s request, defend or pay for the defense of LOMBARD, its Affiliates and their respective directors, officers, employees, agents, subcontractors, representatives(each, a “LOMBARD Indemnified Party”) from and against all Third Party claims, demands and causes of action (“Claims”) and all judgments, settlements, liabilities, fines, penalties, costs and expenses arising from Claims (“Losses”) to the extent arising out of or resulting from (i) any Products manufactured by MICROPORT which caused any injury or damage; (ii)MICROPOR’s breach of this Agreement, and (iii) MICROPORT’s failure to comply with Applicable Laws.
 10
  
 
  
  
 (b)               LOMBARD shall indemnify and hold harmless, and at MICROPORT’s request, defend or pay for the defense of MICROPORT, its Affiliates and their respective directors, officers, employees, agents, subcontractors, representatives (each, a “MICROPORT  Indemnified Party”) against all Claims and Losses brought against MICROPORT that: (i) any Products themselves, or any portion thereof, or any processes, equipment or methods used to manufacture the Products constitutes an infringement of any trademark, copyright, patent or other intellectual property right of any Third Party; (ii) any Products which caused any injury or damage; and(iii) that arise or are alleged to have arisen as a result of breach by LOMBARD of any term of this Agreement. 
 (c)                In no event shall either Party have any liability to the other Party or any Third Party for any loss of revenue, loss of profit, loss of data or loss of goodwill, or for any indirect, special or consequential loss or damage arising out of or in connection with this Agreement or any collateral contract, whether in contract, tort (including negligence) or otherwise.
 Article 9
FORCE MAJEURE
 9.01          Performance Delay.  The time for performance of a Party impacted by a Force Majeure Event, other than the satisfaction of payment obligations that have accrued under this Agreement, is excused, without liability, for the duration of time that the Force Majeure Event impairs such Party’s ability to perform its obligations under this Agreement.
 9.02          Notice.  The Party whose performance is affected by a Force Majeure Event (the “Affected Party”) shall give prompt written notice to the other Party stating the details and expected duration of the event. Once notice is given of a Force Majeure Event, the Parties shall keep each other reasonably informed of the situation until the Affected Party’s performance is no longer affected by the Force Majeure Event or this Agreement is terminated, whichever occurs first. If the performance of the Affected Party does not resume within ninety (90) days of the occurrence of a Force Majeure Event, the other Party shall have the right to terminate this Agreement without penalty, except LOMBARD’s satisfaction of payment obligations that have accrued under this Agreement shall survive the termination of this Agreement. Each Party has full management discretion in dealing with its own labor issues.
 Article 10
MISCELLANEOUS
 10.01      Governing Law and Dispute Resolution.  This Agreement shall be governed by and construed in accordance with Chinese law (The United Nations Convention on International Sale of Goods shall not apply to This Contract). Any dispute, controversy, difference or claim arising out of or relating to this Agreement ,including the existence, validity, interpretation, performance, breach or termination thereof or any dispute regarding non-contractual obligations arising out of or relating to it shall be settled through friendly negotiations. In case no settlement can be reached through such negotiations, any such dispute, controversy, difference or claim shall be referred to and finally resolved by arbitration administered by the Hong Kong International Arbitration Centre (“HKIAC”) under the HKIAC Administered Arbitration Rules in force when the notice of arbitration is submitted.  The seat of arbitration shall be Hong Kong and the number of arbitrators shall be three and the arbitration proceedings shall be conducted in English.
 11
  
 
  
  
 10.02      Integration; Amendments.  This Agreement and Exhibits referred to in this Agreement and the Confidentiality Agreement between the Parties, together with the Technology, Licensing and Manufacturing Agreement, Brazil Registration and Distribution Agreement, and the China Registration and Distribution Agreement constitute the entire agreement between the Parties with respect to the subject matter hereof and supersede all previous arrangements with respect to the subject matter hereof, whether written or oral.  Any amendment or modification to this Agreement shall be made in writing signed by both Parties.
 10.03      Notices.  Any consent, notice or report required or permitted to be given or made under this Agreement by one of the Parties hereto to the other shall be in writing and (a) delivered by hand, (b) sent by internationally recognized delivery service, (c) sent by registered or certified mail, return receipt requested, postage prepaid, or (d) sent by facsimile transmission confirmed by prepaid, registered or certified mail letter, and shall be deemed to have been properly served to the addressee upon receipt of such written communication, in any event to the following addresses:
 If to MICROPORT:    MICROPORT ENDOVASCULAR (SHANGHAI) CO., LTD.
Building #1, 3399 Kangxin Rd., SIMZ Century Medicine Park Shanghai 201318, P. R. China
Attention: Zhu Qing
Email:qzhu@microport.com
 If to LOMBARD:       LOMBARD MEDICAL LIMITED 

888 Prospect Street, Suite 200
                                     La Jolla, CA   92037Attention: Bill Kullback
Email: bill.kullback@lombardmedical.com
 Either Party may change its address to which notices shall be sent by giving notice to the other Party in the manner herein provided.
 10.04      Further Assurances.  Each Party agrees to execute, acknowledge and/or deliver such further instruments, and to do all other acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement.
 12
  
 
  
  
 10.05      No Strict Construction.  This Agreement has been prepared jointly and shall not be strictly construed against either Party.
 10.06      Headings.  The captions or headings of the sections or other subdivisions hereof are inserted only as a matter of convenience or for reference and shall have no effect on the meaning of the provisions hereof.
 10.07      No Implied Waivers; Rights Cumulative.  No failure on the part of a Party to exercise, and no delay in exercising, any right, power, remedy or privilege under this Agreement, or provided by statute or at law or in equity or otherwise, shall impair, prejudice or constitute a waiver of any such right, power, remedy or privilege or be construed as a waiver of any breach of this Agreement or as an acquiescence therein, nor shall any single or partial exercise of any such right, power, remedy or privilege preclude any other or further exercise thereof or the exercise of any other right, power, remedy or privilege.
 10.08      Severability.  If any provision hereof should be held invalid, illegal or unenforceable in any respect in any jurisdiction, the Parties hereto shall substitute, by mutual consent, valid provisions for such invalid, illegal or unenforceable provisions, which valid provisions in their economic effect are sufficiently similar to the invalid, illegal or unenforceable provisions that it can be reasonably assumed that the Parties would have entered into this Agreement with such valid provisions.  In case such valid provisions cannot be agreed upon, the invalidity, illegality or unenforceability of one or several provisions of this Agreement shall not affect the validity of this Agreement as a whole, unless the invalid, illegal or unenforceable provisions are of such essential importance to this Agreement that it is to be reasonably assumed that the Parties would not have entered into this Agreement without the invalid, illegal or unenforceable provisions.
 10.09      Assignment.  Neither party may assign, directly or indirectly, all or part of its rights or obligations under this Agreement without the prior written consent of the other party, which consent shall not be unreasonably withheld or delayed.
 10.010  No Third Party Beneficiaries.  No Person, other than MICROPORT, LOMBARD and their respective Affiliates and any permitted assignees hereunder, shall be deemed an intended beneficiary hereunder or have any right to enforce any obligation of this Agreement.
 10.011  Execution in Counterparts.  This Agreement may be executed in any number of counterparts and by facsimile signature, each of which counterparts, when so executed and delivered, shall be deemed to be an original, and all of which counterparts, taken together, shall constitute one and the same instrument.
 10.012  Controlling Agreement.  In the event any term of this Agreement is inconsistent with the terms of a Purchase Order issued by LOMBARD, then the terms of this Agreement shall control.
 13
  

 
    
 10.013  Interpretation.  Except where the context expressly requires otherwise, (a) the use of any gender herein shall be deemed to encompass references to either or both genders, and the use of the singular shall be deemed to include the plural (and vice versa); (b) the words “include”, “includes” and “including” shall be deemed to be followed by the phrase “without limitation” and shall not be interpreted to limit the provision to which it relates; (c) the word “will” shall be construed to have the same meaning and effect as the word “shall”; (d) any definition of or reference to any agreement, instrument or other document herein shall be construed as referring to such agreement, instrument or other document as from time to time amended, supplemented or otherwise modified; (e) any reference in this Agreement to any Person shall be construed to include the Person’s successors and assigns; (f) the words “herein”, “hereof” and “hereunder”, and words of similar import, shall be construed to refer to this Agreement, and not to any particular provision of this Agreement; (g) all references herein to Sections, Exhibits or Schedules shall be construed to refer to Sections, Exhibits or Schedules of this Agreement; (h) the word “notice” means notice in writing (whether or not specifically stated); (i) provisions that require that a Party, the Parties “agree,” “consent” or “approve” or the like shall require that such agreement, consent or approval be specific and in writing, whether by written agreement, letter, approved minutes or otherwise (but excluding e-mail and instant messaging); (j) references to any specific law, rule or regulation, or article, section or other division thereof, shall be deemed to include the then-current amendments thereto or any replacement or successor law, rule or regulation thereof; and (k) the term “or” shall be interpreted in the inclusive sense commonly associated with the term “and/or.”
 (Signature page follows)
  
 14
  
 
  
 

  
 IN WITNESS WHEREOF, the Parties to the Agreement by their duly authorized representatives have executed this Agreement as of the date first written above.
  
  
  	 MICROPORT ENDOVASCULAR (SHANGHAI) CO., LTD.

	 LOMBARD MEDICAL LIMITED

	 By: _____________________________
        
	 By: ___________________________

	 Title: ___________________________
	 Title:___________________________

 [The remainder of this page intentionally left blank]
 

  
 15
  
 
  
  
 Exhibit A – To Be Determined 

 List of Components
    
  16Exhibit 4.28

   
 
 
CHINA REGISTRATION AND DISTRIBUTION AGREEMENT
 This Registration and Distribution Agreement (this “Agreement”) is made and entered into as of April 3,  2017 (the “Effective Date”) by and between:
 LOMBARD MEDICAL LIMITED, a Company organized and existing under the laws of England with registered offices in Lombard Medical House, 4 Trident Park, Didcot, Oxfordshire, OX11 7HJ, United Kingdom( “Company” or “LOMBARD”), and
 MICROPORT ENDOVASCULAR (SHANGHAI) CO., LTD., a company registered in People’s Republic of China, whose registered office is at Building 1, Lane 3399, Kangxin Road, Pudong New District, Shanghai, 201318 P. R. China (“Distributor” or “MP ENDO”).
 The Company and the Distributor may be referred to herein as a “Party” or, collectively, as the “Parties”.
 RECITALS:
 WHEREAS, in connection with the investment in and strategic collaboration between LOMBARD and MICROPORT SCIENTIFIC CORPORATION;
 WHEREAS, Company wishes to appoint Distributor as its exclusive distributor of Products (as defined below) in the Territory (as defined below) subject to the terms and conditions set forth in this Agreement, and Distributor is willing to accept such appointment.
 NOW, THEREFORE, in consideration of their mutual covenants and agreements contained herein, and the mutual benefits to be derived here from, the Parties, intending to be legally bound, hereby covenant and agree as follows:
 COVENANTS:
 ARTICLE 1
DEFINITIONS
 1.01     Capitalized terms in this Agreement shall have the following meanings:
 “Affiliate” shall mean, with respect to any Person, any other Person which controls, is controlled by, or is under common control with such Person.  A Person shall be regarded as in control of another entity if it owns or controls more than fifty percent (50%) of the equity securities of the subject entity entitled to vote in the election of directors (or, in the case of an entity that is not a corporation, for the election of the corresponding managing authority).  Notwithstanding the foregoing, with respect to a Party, “Affiliate” does not include a purchaser or holder of such Party’s equity securities that acquired or acquires such equity securities solely for investment purposes such as a venture capital fund or private equity fund.
 “Agreement” shall mean this Registration and Distribution Agreement, including the Exhibits attached hereto, as such may be amended from time to time.
 1
  
  
  
 “Annual Minimum Volume” shall mean the minimum purchase requirements for the Products for each calendar year during the term of this Agreement established via a mechanism of mutual agreement within ninety (90) days after the relevant Approval Date for each   Product and thereafter by October 31st of each of the prior year. Distributor shall apply good faith efforts to meet the Annual Minimum Volume. Notwithstanding anything to the contrary in this Agreement, Distributor’s failure to meet the same shall not be a material breach as described in Section 15.01 hereof, but such failure will trigger a requirement by Distributor to purchase the Annual Minimum Volume for the year in question, subject to good faith discussion between the parties. In no event Distributor shall be held liable to Company for any damage, loss or otherwise due to such failure.
 “Approval Date(s)” shall mean the issuance date of CFDA Registration Certificates for either of the Products.
 “Bankruptcy Event” shall mean the Person in question becomes insolvent, or voluntary or involuntary proceedings by or against such person or entity are instituted in bankruptcy or under any insolvency law, or a receiver or custodian is appointed for such person or entity, or proceedings are instituted by or against such person or entity for corporate reorganization or the dissolution of such person or entity, which proceedings, if involuntary, shall not have been dismissed within sixty (60) days after the date of filing, or such person or entity makes an assignment for the benefit of its creditors, or substantially all of the assets of such person or entity are seized or attached and not released within sixty (60) days thereafter.
 “Business Days” shall mean Monday through Friday, and shall exclude Saturday, Sunday, and public holidays in P.R. China.
 “CFDA Registration Certificate(s)” shall mean Registration Certificate(s) of the Products issued by CFDA.
 “CFDA” shall mean China Food and Drug Administration.
 “Change of Control” shall mean with respect to a Party, a change in ownership or control of such Party effected through (i) the acquisition, directly or indirectly, by any Person or related group of Persons different from the persons holding those securities immediately prior to such transaction, of beneficial ownership of securities possessing fifty percent (50%) or more of the total combined voting power of such Party’s outstanding securities, (ii) a merger or consolidation in which securities possessing fifty percent (50%) or more of the total combined voting power of such Party’s outstanding securities are transferred to a Person or Persons different from the persons holding those securities immediately prior to such transaction; or (iii) the sale, transfer, exclusive license or other disposition of all or substantially all of such Party’s assets, or any material technology or intellectual property of such Party; provided, however, that any internal restructuring, reorganizing, or event where the existing shareholders retain control, shall not constitute a Change of Control for the purposes of this Agreement.
 “FDA” shall mean the United States Department of Health and Human Services Food and Drug Administration or any successor agency.
 2
  
  
  
 “Force Majeure Event” shall mean any event beyond the reasonable control of the Party affected by such event and which occurs without the fault or negligence of such Party or any of its subcontractors or suppliers, including, but not limited to, an act of God, delay or loss in transportation, fire, flood, earthquake, storm, war, riot, revolt, act of a public enemy, embargo, explosion, civil commotion, strike, act of terror, labor dispute, loss or shortage of power, impossibility or delay of obtaining raw materials or shortage in supply of raw materials or any law, rule, regulation, order by any Governmental Authority except for any action regarding public policy. In each instance, the failure to perform must be beyond the reasonable control of the first Party.
 “Governmental Authority” shall mean any court or any governmental or other administrative or regulatory body, authority, department, ministry, agency, tribunal, or commission in the Territory including CFDA.
 “Person” shall mean any natural person, corporation, firm, business trust, joint venture, association, organization, company, partnership or other business entity, or any government, or any agency or political subdivisions thereof.
 “Product(s)” shall mean those products manufactured by Company as described in Exhibit A attached hereto.  Product(s) may be changed, deleted or added by the mutual consent in writing of Company and Distributor.  Notwithstanding anything in this Agreement to the contrary, and at Distributor’s election but not obligation, Distributor is free to determine whether and when to distribute the Product of AlturaTM in the Territory.
 “Purchase Order” or “Order” shall mean individual, written purchase order placed by Distributor for the purchase of Products from Company.
 “Purchase Price” shall mean the transfer price to Distributor for each of the Products, which price may be revised from time to time through consultation and agreement in writing between the Parties, taking into account the prevailing market prices of Similar Products.  Such revisions shall apply to the Orders placed by Distributor after the effective date of the revision.  Price changes shall not affect unfulfilled Purchase Orders placed by Distributor prior to the effective date of the revision.
 “Similar Products” shall mean any products for use by vascular surgeons similar to the Products, for which Distributor holds the exclusive distribution rights granted by Company that may be regarded as directly competitive or substitutable of the Products which will be mutually judged and agreed upon by Distributor and Company.
 “Specifications” or “specifications” shall mean the material, design and quality standards appropriate for their intended use for the Products supplied by the Company to the Distributor, as such may from time to time be amended by written agreement of the Parties.
 “Term” shall have the meaning set forth in Article 14.
 “Territory” shall, for the purposes of this Agreement, mean China, Hong Kong and Macau.
 “Third Party” shall mean any individual or entity other than a Party or an Affiliate of a Party.
 3
  
  
  
 ARTICLE 2
APPOINTMENT
 2.01     Company hereby appoints Distributor, and Distributor accepts such appointment, as Company’s exclusive distributor to market, promote, distribute and sell the Products within the Territory.  Company shall not, directly or indirectly, supply the Products to any Third Party other than Distributor in the Territory within the Term of this Agreement.
 2.02     Company agrees that Distributor may, at its sole discretion, appoint one or more Persons to act as sub-distributors (each a “Sub-distributor” and, collectively, the “Sub-distributors”) to market, promote, distribute and sell the Products within any portion of the Territory, as the case may be.
 2.03     In the event Company intends to market, promote, distribute and sell any new listing Similar Products in the Territory, Distributor shall, under identical terms and conditions, reserve the preemptive right, which may be exercised within sixty (60) days of receipt of notice by Distributor, to be appointed as the exclusive distributor for the said similar Products.  For the avoidance of doubt, once Distributor claims to exercise the said preemptive right, such new listing Similar Products shall be deemed as having been added to Exhibit A.
 2.04     The relationship of Company and Distributor established under this Agreement is that of independent contractors, and nothing contained herein shall be construed as to: (i) give either Party the power to direct and control the day-to-day activities of the other; or (ii) allow one Party to create or assume any obligation on behalf of the other for any purpose whatsoever.
 2.05     Distributor shall use its best efforts in the promotion and sale of the Products.  Upon the earlier of the Approval Date for either of the Products, Company shall provide Distributor with training and marketing supports (“Training and Marketing Support”) with respect to promotion of the Products within the Territory. The amount of the Training and Marketing Support equals a certain fixed dollar amount established via a mechanism of mutual agreement after the relevant Approval Date for each Product and thereafter by October 31st of each of the prior year for each calendar year during the Term of this Agreement.  The contribution date, manner and details of Company’s contribution towards the Training and Marketing Support shall be mutually agreed between the Parties following good faith discussions and taking into account the purchase amount, Company’s budget and market needs.
 2.06     Upon Distributor’s reasonable request, Company shall provide to Distributor a limited quantity of Product samples (“Product Samples”), which quantity shall be determined in good faith by mutual agreement of the Parties and included within the Training and Marketing Support fixed dollar amount agreed upon in Section 2.05.  Distributor shall use such Product Samples solely for the promotion of the Product in the Territory pursuant to this Agreement. Marketing Support limits defined above shall apply to the cost of Product Samples. For the avoidance of doubt, Marketing Support limits defined above shall not apply to cost of free samples defined under Section 6.01 hereof.
 4
  
  
  
 2.07     Company agrees that the tenders involving the Products which are held in each areas or sites of the Territory (the “Tenders”) shall be participated by Distributor in the name of Distributor.  Company shall provide Distributor with any required Tender support documents.  Company shall provide reasonable assistance to Distributor to participate in the Tenders.
 2.08     Company shall respond to all inquiries from Distributor concerning matters pertaining to this Agreement within a reasonable time.  Upon reasonable request from Distributor, Company shall provide Distributor with information from the US, European and Japanese markets as to general market movement, competitors’ prices and strategies, names of Company’s major customers (users) and other information that may help Distributor to promote and sell the Products in the Territory.
 ARTICLE 3
TERMS OF PURCHASE OF PRODUCTS
 3.01     Distributor will order the Products by means of Purchase Order transmitted by facsimile or e-mail to Company.  Distributor shall have the right but not obligation to place the Order on a monthly basis.  The Order shall specify applicable prices, Product code, Product quantities, requested shipping schedule, shipping instructions, and other matters necessary for the individual transaction.
 3.02     Company shall notify Distributor of its acceptance or rejection of the Order in written form within five (5) Business days after receipt of such Order from Distributor.  If rejected, the reasons for the rejection, and if rejected by Company, the quantities of Products on the rejected Order shall be deducted from Annual Minimum Volume for the applicable year.  In default of written confirmation of acceptance or rejection within five (5) Business days, the Order shall be deemed rejected.  Under such circumstance, Distributor shall assume no obligation to either the Order or the written acceptance by Company thereafter, unless an agreement regarding the Order can be reached between Company and Distributor which shall be confirmed in writing.  Any Order submitted by Distributor and accepted by Company shall be binding upon the Parties and may not be modified, rescinded or cancelled by either Party without the written agreement of the other Party.  If there are any inconsistencies between the terms of any Order and the terms of this Agreement, the terms of this Agreement shall govern.
 3.03     Within ten (10) Business Days after the beginning of each calendar quarter, Distributor shall forward to Company non-binding forecasts of Product requirements for the next calendar quarter. Company shall at all times maintain an adequate supply of Products in its inventory as indicated in the said forecasts to meet Distributor’s Product requirements shown in the Order.  Distributor shall not be obligated to meet Annual Minimum Volume if Company is not able to provide Distributor with Products on a timely basis.
 3.04     Dates of shipment will be agreed upon in writing between the Parties with respect to each Order.  Company shall ship the Products as per the agreed shipping date.  Company shall deliver the Products to Distribution all in accordance with the applicable Order and Specifications.  All Products shipped pursuant to the terms of this Agreement shall be suitably packed for proper shipment in Company’s standard shipping cartons, marked for shipment to Distributor’s address set forth in Section 17.04 and delivered to Distributor in accordance with EXW Company Facility (INCOTERMS 2010) or such other facility as agreed by the Parties, at which time ownership for such Products and risk of loss shall pass to Distributor, unless otherwise specified in the Order accepted by Company.
 5
  
  
  
 3.05     The remaining shelf life of the Products received by Distributor shall be at least nine (9) months as of the date Distributor receives such Products.
 3.06     Company warrants that all Products will be free of defects in material, design and workmanship and in accordance with their applicable Orders, Specifications and all applicable laws.
 3.07     Distributor shall inspect the Products received for conformity with Distributor’s Order within thirty (30) Business days after receipt thereof (“Inspection Period”).  Should during such Inspection Period the Products be found to have any defects or non-conformities, Distributor shall serve to Company a written notice addressing such defects or non-conformities in detail.
 3.08     If any Products are rejected pursuant to Section 3.07, upon receipt of the properly rejected Products, Company shall, as promptly as possible but no later than fifteen (15)Business Days after receipt by Distributor of the properly rejected Products, evaluate them to determine if they are defective.  In the event Company concurs that the properly rejected Products do not comply with the agreed-to Specifications (“Defective Products”), then, at Company’s option:
 (a)        Company shall, at its option, within thirty-five (35) Business Days or as otherwise agreed by the Parties, complete the repair or replacement the Defective Products to comply with the applicable agreed-to Specifications.  The shipment of the said return and replacement shall be borne by Company; or
 (b)        Distributor may without any liability to Company cancel the relevant Order in full or partially with Defective Products.
 3.09          In the event that Distributor fails to supply, sell, distribute the Products due to any of Company’s failure to deliver the Products (inclusive of the replacement Products, if applicable) on a timely basis  in accordance with this Agreement, the corresponding quantities of the above mentioned Products shall be deducted from Annual Minimum Volume for the applicable year.  In addition, Company shall bear and fully indemnify Distributor against any and all loss, damage, cost and expense (including any damages claimed by any Third Party) incurred by Distributor directly as a result of such delay subject to the Purchase Price of the Products not appropriately supplied. Such indemnification may be directly deducted from the Purchase Price payable or to be paid by Distributor to Company.
 ARTICLE 4
PURCHASE PRICE AND ANNUAL MINIMUM VOLUME
 4.01     Within ninety (90) days after the corresponding Approval Date for certain Products, and at least sixty (60) days prior to the commencement of each calendar year thereafter, the Parties shall, through negotiation in good faith, determine the Purchase Price and Annual Minimum Volume of such Products for each calendar year during the term of this Agreement.
 6
  
  
  
 4.02     If the currency exchange rate between Renminbi  (RMB) and United States Dollars (US$) fluctuates by up to plus or minus five percent (5%) from the exchange rate of RMB:US$ which is announced by China Foreign Exchange Trade System (“CFETS”) on its website(http://www.chinamoney.com.cn/english/) on the date that the latest Purchase Price has been agreed between the Parties, Distributor will bear or benefit from 100% of currency exchange rate impact, that is to say, the Purchase Price shall not be affected by currency exchange rate fluctuation of up to plus or minus five percent (5%). Where such fluctuation exceeds the threshold of five percent (5%) or above up to maximum of ten percent (10%), Company shall bear or benefit from the currency exchange rate fluctuation impact, that is to say Purchase Price shall be revised by the Parties in accordance with the rate of exchange rate fluctuation.  If the currency exchange rate between Renmenbi (RMB) and United States Dollars (US$) fluctuates more than plus or minus ten percent (10%), both Parties shall promptly and in good faith negotiate an adjustment of the Purchase Price applicable to the Products.
 4.03     As Chinese health policy on price and medical insurance is currently undergoing significant changes, it is necessary for the Parties to review and analyze the Purchase Price and Annual Minimum Volume each calendar year.  If winning bid price of Product declines, the Parties agree to adjust the price and/or the Annual Minimum Volume through friendly negotiation accordingly.
 4.04     Company undertakes to pay any national or local taxes imposed in United Kingdom or elsewhere outside Territory that may be required to ship the Products to Distributor.  Distributor undertakes to pay any taxes that may be applicable to its business in relation to the Products according to the laws and regulations prevailing in the Territory.
 ARTICLE 5
PAYMENT
 5.01     Company shall provide an invoice to Distributor for each accepted Order specifying the Purchase Price of the ordered Products.  Distributor shall pay to Company the full amount shown on each of such invoice in US$ by wire transfer (T/T) within ninety (90) calendar days after receipt of the Products (“Payment Term”).
 ARTICLE 6
GOVERNMENTAL APPROVAL
 6.01     Distributor shall use commercially reasonable efforts, to obtain CFDA Registration Certificate for the Products.  Distributor shall be responsible for necessary costs and expenses associated with obtaining, holding and maintenance of CFDA Registration Certificate.  Company shall cooperate fully with Distributor and provide all necessary assistance, including without limitation, Product specifications, free samples (for the purpose of type test), technical documentation, validation and other data as required by Governmental Authority from time to time to support the obtaining, holding and maintenance of CFDA Registration Certificate for the Products, including but not limited to, testing requirements, existing human clinical trial data (if necessary), design history files and shall bear any costs associated with providing such cooperation and assistance.
 7
  
  
  
 6.02     In the event a clinical trial is required by Governmental Authority for obtaining, holding and maintaining CFDA Registration Certificate for the Products, the Parties shall, prior to initiating the clinical trial, through good faith negotiation,  determine  to what extent and in what proportions each Party shall be required to contribute to the clinical trial costs, including without limitation, payment made to clinical trial organization and contract research organization, and supply of Products used in such trial.
 6.03 Company shall be responsible for obtaining, at its own expense, any required export licenses and other permits from any relevant Governmental Authority for the export of the Products to Distributor.  Distributor shall be responsible for, at its own expense, obtaining and maintaining any required licenses and permits and for satisfying all formalities as may be required to import the Products by Distributor into the Territory in accordance with the prevailing legislation.  Distributor shall maintain the “Medical Device Business License” required by Governmental Authority in order to distribute the Products during the Term of this Agreement.  Each Party shall cooperate fully with the other and provide all reasonable assistance to the other in connection with obtaining and maintaining any licenses or permits contemplated by this Section 6.02.
 6.04     During the term of this Agreement, each Party hereto shall comply with any and all applicable laws including, but not limited to, anti-bribery law, rules and regulations applicable to its activities pursuant to this Agreement.
 ARTICLE 7
DISCONTINUATION AND MODIFICATION OF PRODUCTS
 7.01     In the event of any discontinuation (“Discontinuation”) of the Products in the Territory (“Discontinued Products”), Company shall notify Distributor in writing at least six (6) months prior to such Discontinuation. Despite such Discontinuation, Distributor is entitled to retain the right to sell its remaining inventory of the said Discontinued Products; (ii) request the Company to repurchase any of such Discontinued Products at the original Purchase Price of the same paid by Distributor.  Notwithstanding the foregoing, in the case of bid winning Products in the Territory, Company shall ensure the supply of such Discontinued Products to fulfill all Orders placed by Distributor from time to time for any tenders in effect.  
 7.02     Company may change, modify, or alter the design or applicable Specification (“Modification”) of the Products supplied hereunder and initiate the manufacture of the modified products (“Modified Products”) provided that written notice thereof is addressed to Distributor (i) at least sixty (60) days prior to the said manufacture in the case of material Modification (“Material Modification”) required by Applicable Law for CFDA registration (“Modification Registration”), and in such cases Company shall at all times maintain a sufficient supply of unmodified Products to fulfill all Orders placed by Distributor from time to time until the completion of Modification Registration; or (ii) at least thirty (30) days prior to the said manufacture in other cases.
 8
  
  
  
 7.03     Notwithstanding the above Section 7.01 & 7.02, neither Discontinuation nor Modification provided therein respectively shall lead to any loss and damage incurred by Distributor. Otherwise, Company is obliged to compensate for all such loss and damage.
 ARTICLE 8
RECALL
 8.01     Pursuant to any reporting requirements of Governmental Authority, Company may be required to report to the said Governmental Authority information that reasonably suggests that a Product may have caused or contributed to death or serious injury or has malfunctioned and that the device would be likely to cause or contribute to a death or serious injury if the malfunction were to recur.  The Parties hereto agree to supply to the other any such information twenty-four (24) hours after becoming aware of it so that each can comply with the aforesaid reporting requirements.  In the event that Company is required by any Governmental Authority to recall the Products or if Company voluntarily initiates such recall, Distributor shall reserve the right to return the said recalled Products to Company following the execution of a recall.  In cases where such recall results from defects in design, material or workmanship of the Products, Company shall, within ninety (90) days after receipt of the returned Products, refund the original Purchase Price of such Products paid by Distributor subject to the recouping of costs borne by the Company for such Products manufactured by MicroPort.
 8.02     Notwithstanding the foregoing paragraph, such return shall, by no means, relieve Company’s liability in relation to the recalled Products.  In cases where such recall results from defects in design, material or workmanship of the Products, Company shall bear all costs and expenses of any recall, including, without limitation, expenses or obligations to any Third Parties, the costs of notifying customers and costs associated with any of the shipment of recalled Products, whether from customer to Distributor or Company or otherwise.
 ARTICLE 9
ADVERSE EVENTS AND CUSTOMER COMPLAINTS
 9.01     In the event of any adverse events caused by a Product or any customer complaints of Product in the Territory (collectively, the “Events”), Company shall respond to Distributor in writing of such Events without any undue delay after receiving Distributor’s notice.  Upon Distributor’s request, Company shall give Distributor assistance to deal with the Events including but not limited to providing the professional advice concerning the Events, preparing and providing any testing reports, data, results or any other documents, as the case may be.  In cases where such Events are as a result of defects in the design, material or workmanship of the Products, Company shall be responsible for relevant costs incurred by Distributor in connection with the Events.  The Parties shall negotiate in good faith to determine the solution to the Events.
 9.02     Notwithstanding the foregoing paragraph, Company shall be responsible for the compensation paid to customer in connection with or arisen out of any personal injury or property damage caused by defects in the design, material or workmanship of the Products.
 9
  
  
  
 ARTICLE 10
INTELLECTUAL PROPERTY RIGHTS
 10.01   Company hereby grants to Distributor (and its Sub-distributors), free of charge, and subject to Company’s review and approval of use, the non-exclusive right to use the trademarks, service marks, trade names, logos or other words or symbols identifying the Products, related services or Company’s business (the “Trademarks”) on its advertising and promotional materials, stationery, signs, labels and packaging in order to convey that it is acting as distributor of the Products in the Territory on behalf of Company.  This provision does not grant the right or license to use any of the Trademarks in the enterprise name of Distributor.  Distributor may not use any of the Trademarks in any way beyond the scope specified in this Agreement; any such use of any of the Trademarks by Distributor shall constitute infringement by Distributor of Company’s exclusive rights to the relevant Trademark.
 10.02   Distributor shall not do, or omit to do, anything in its use of the Trademarks that could adversely affect their validity and shall promptly notify Company in writing of (i) any claim against Distributor that any Product or part thereof or any advertising or promotional materials supplied to Distributor by Company infringes any patent, trademark or copyright and (ii) any suit, action or proceeding brought against Distributor on the basis of any such claim.  Company shall defend or settle such suit, action or proceeding properly to the extent that it will not cause any adverse effects on the sales of Products in the Territory, and the costs thereof (including any final award of damages) shall be borne entirely by Company.  Distributor shall provide Company, at Company’s expense, with all the information, assistance and authority necessary to enable Company to defend such claim.
 10.03   Distributor shall promptly inform Company in writing if it becomes aware of any infringement of, or unfair competition with respect to, the Trademarks or any Company patent or copyright by any Third Party.  Company shall prosecute at its own expense any claims and any suits, proceedings or actions arising therefrom.  Distributor shall cooperate fully with Company in the prosecution of any such suit, proceeding or action.
 10.04   If it is adjudicatively determined that any Product infringes, or in Company’s sole opinion, may be found to infringe a Third Party’s patent, or if the sale or ,use of the Products is, as a result, enjoined, then Company shall, at its option and expense, either: (i) procure for Distributor the right under such patent to sell or use, as appropriate, the Products; or (ii) replace the Products with other non-infringing functionally equivalent products; or (iii) modify the Products to make the Products functionally equivalent and non-infringing; or (iv) if the use of the Products is prevented by injunction, discontinue Product sales under the Agreement and remove any Products in Distributor’s inventory and refund the aggregate payments paid therefor by Distributor.
 ARTICLE 11
CONFIDENTIALITY
 11.01   Each of the Parties hereto acknowledges that by reason of its relationship to the other Party hereunder it will have access to certain information and materials concerning the other Party’s and/or its Affiliates’ business, including business plans, trade secrets, customers, technology and products (including the Products) that are confidential and/or of substantial value, and the value of such information would be impaired if disclosed to any Third Parties.
 10
  
  
  
 11.02   Each of the Parties hereto agrees that it will not use in any way for its own account or the account of any Third Party, nor disclose to any such Third Party, confidential information revealed to it by the other Party and/or its Affiliates until and unless (i) such information becomes public through means other than through breach of this Agreement; (ii) to the extent required by any order of any court of competent jurisdiction or any order, enquiry or investigation by any competent judicial, governmental, exchange or regulatory body; or (iii) as may be required by law. Upon request of either of the Parties hereto, the other Party shall advise whether or not it considers any particular information or materials to be confidential.
 ARTICLE 12
REPRESENTATION AND WARRANTY
 12.01   Company represents and warrants that: (i) it has the right to enter into this Agreement and its performance of this Agreement will be free and clear of liens and encumbrances; (ii) entering into this Agreement will not cause Company to breach any other agreements to which it is a party; (iii) the Products, or any portion thereof, do not infringe any trademark, copyright, patent or other intellectual property rights of any Third Party with respect to Products.
 12.02   Distributor represents and warrants that: (i) it has the right to enter into this Agreement and its performance of this Agreement will be free and clear of liens and encumbrances and (ii) entering into this Agreement will not cause Distributor to breach any other agreements to which it is a party.
 12.03   If Distributor sells, consigns or otherwise transfers the products to any purchaser, Company hereby agrees to extend to such purchaser a warranty against defects in design, material or workmanship (“Purchaser Warranty”).  Company shall pay for the return and/or replacement of Products that prove to be defective.  The Purchaser Warranty set forth in this Section 12.03 in respect of each Product delivered hereunder shall expire upon the earlier of: (i) one (1) year after the sale by Distributor to the original purchaser; or (ii) the expiry date of such Product.  Company shall indemnify Distributor for all costs and expenses in connection with or arising out of return, replacement or rejection of any Products in accordance with this Section 12.03.  If compulsory law in any jurisdiction within the Territory requires warranties, which are more favorable to the purchaser than stated in the foregoing sentence, Distributor shall notify Company hereof in writing.
 12.04   Anti-Bribery Obligation. Distributor agrees that in performing its duties under this Agreement, it will not violate:  (i) the applicable laws and regulations of the People’s Republic of China (“PRC”), including all PRC anti-bribery laws and regulations; (ii) the laws and regulations of the United States of America, including the Foreign Corrupt Practices Act (“FCPA”); (iii) the laws and regulations of the United Kingdom, including the UK Bribery Act 2010; or (iv) the anti-bribery laws of any other relevant state (all aforementioned laws collectively referred to hereinafter as the “Anti-Bribery Laws”).
 11
  
  
  
 Distributor agrees that in performing its duties under this Agreement it will not offer, promise, or make any payments, loans, gifts of money, valuables, goods, or anything else of value (whether such value is assessable or not):
 (a)      to any customer or any employee of any customer, intending to induce any person to perform improperly one of their functions in their position of trust and responsibility, or as a reward for improper performance, in order to buy or sell goods or services, or in order to obtain or retain business or a business advantage;
 (b)       to an official or employee of any government; or to an official or employee of any department, agency, or instrumentality of a government; or to an employee of any corporation or entity owned or controlled by the government of the PRC or any other nation; or to an immediate family member of such officials or employees for the purpose of influencing such officials or employees in order to obtain any improper advantage, or in order to assist in obtaining or retaining business;
 (c)      to any political party, party official, or political candidate for the purpose of influencing such officials or candidates in order to obtain any improper advantage, or in order to assist in obtaining or retaining business; or
 (d)      to any other person if Distributor knows or has reason to believe that any part of the payment, loan, gift or thing of value will be given directly, indirectly, or through a third party to any of the persons or for any of the purposes described in the three bullet points immediately above.
 Distributor acknowledges that Company has not authorized it in any manner to violate any relevant law or regulation, including any Anti-Bribery Laws, and agrees that it will not accept any purported future authorization that is made whether orally or in writing.
 In the event it is adjudged or determined by any court of competent jurisdiction or any Governmental Authority that the Distributor has violated or failed to comply fully with any of its obligations under this Section 12.04 and/or committed any violations of the Anti-bribery Laws, it would be deemed a material breach of this Agreement and this Agreement may be terminated immediately pursuant to Article 15 hereunder.  Distributor shall fully indemnify and hold the Company harmless against any and all claims, losses or damages arising from or related to such violation.
 ARTICLE 13
INDEMNIFICATION
 13.01   Distributor shall defend, indemnify and hold harmless Company, its Affiliates and their respective directors, officers, employees, agents, subcontractors, representatives (each, a “Company Indemnified Party”) from and against all Third Party claims, demands and causes of action (“Claims”) and all judgments, settlements, liabilities, fines, penalties, costs and expenses arising from Claims (“Losses”) to the extent arising out of or resulting from (i) Distributor’s breach of this Agreement, (ii) personal injury, death or property damage sustained by any Person resulting from any intentional or gross negligent act or omission by Distributor, any of its employees or authorized representatives in connection with the shipping, handling or storage of the Products which are not consistent with the representations, information or data provided to Distributor by Company; or (iii) Distributor’s failure to comply with applicable laws in the import, storage, distribution or marketing of the Products.
 12
  
  
  
 13.02   Company shall defend, indemnify and hold harmless Distributor, its Affiliates and their respective directors, officers, employees, agents, subcontractors, representatives (each, a “Distributor Indemnified Party”) from and against all Third Party claims, demands and causes of action (“Claims”) and all judgments, settlements, liabilities, fines, penalties, costs and expenses arising from Claims (“Losses”) to the extent arising out of or resulting from (i) Company’s breach of this Agreement, (ii) personal injury, death or property damage sustained by any Person resulting from any intentional or gross negligent act or omission by Company, any of its employees or authorized representatives in connection with the shipping, handling or storage of the Products which are not consistent with the representations, information or data provided to Company by Distributor; or (iii) Company’s failure to comply with applicable laws in the import, storage, distribution or marketing of the Products. 
 13.03   Unless expressly stated otherwise in this Agreement, in no event shall either Party have any liability to the other Party or any Third Party for any loss of revenue, loss of profit, loss of data or loss of goodwill, or for any indirect, special or consequential loss or damage arising out of or in connection with this Agreement or any collateral contract, whether in contract, tort (including negligence) or otherwise.
 ARTICLE 14
TERM
 14.01   Term.  This Agreement shall become effective from the Effective Date and will remain in force until the fifth anniversary of the Approval Date for either of the Products (whichever comes later) unless terminated earlier in accordance with Section 15.01 hereof.
 14.02   Subject to mutual agreement of the parties, at the end of the Term, Distributor shall, under identical terms and conditions, has the preemptive right to remain the exclusive distributor for the Products in the Territory after the expiry of this Agreement.
 ARTICLE 15
TERMINATION
 15.01   To the extent that either Party shall elect to terminate this Agreement for cause, or any applicable law provides that cause, each of the following, shall constitute cause for such termination, and this Agreement may be terminated prior to the expiry of the Term upon written notice to the other Party, as follows: (i) by a Party, effective immediately, if the other Party should experience a Bankruptcy Event; (ii) by a Party, effective immediately, if the other Party commits a material breach of any term of this Agreement and (if that breach is remediable) fails to remedy that breach within thirty (30) days of that Party being required in writing to do so; (iii)  by a Party, effective immediately, if Change of Control occurs in the other Party; (iv) by a Party, in accordance with Article 16 hereof, if any Force Majeure Event occurs.
 13
  
  
  
 15.02   In the event this Agreement is terminated by Distributor in accordance with Section 15.01(i), Distributor may, at its sole option, (i) retain the right to sell its remaining inventory of Products; or (ii) request Company or Company’s designee to repurchase any Products in Distributor’s inventory provided such Products are saleable, conforming to the agreed-to Specifications.  In such case, Company shall refund the aggregate payments paid therefore by Distributor within thirty (30) days after receipt of the said Products.
 15.03   In the event this Agreement is terminated by Company in accordance with Section 15.01(ii), Company may, at its sole option, obligate Distributor to sell to Company any Products in Distributor’s inventory provided such Products are saleable, conforming to the agreed-to Specifications.  In such case, Company shall refund the aggregate payments paid therefore by Distributor within thirty (30) days after receipt of such Products.
 15.04   In the event this Agreement is terminated by Distributor in accordance with Section 15.01(ii) or (iii), Distributor may, at its sole option, (i) retain the right to sell its remaining inventory of all Products; or (ii) request Company or Company’s designee to repurchase any Products in Distributor’s inventory provided such Products are saleable, conforming to the agreed-to Specifications.  In the case of repurchase of any Products under this 15.04 (ii), Company shall refund the aggregate payments paid therefore by Distributor within thirty (30) days after receipt of the said Products.  In addition, Company shall pay to Distributor a payment equal to aggregate amount of the sales of Products during the period of most recent twelve (12) calendar months in the Territory (the “Twelve (12)-month Sales Payment”) provided that, if such termination is due to Change of Control on the part of Company, and Distributor or its Affiliates are in control of Company through an acquisition, merger, consolidation or otherwise, directly or indirectly, Company has no obligation to pay such Twelve (12)-month Sales Payment. Company shall also reimburse Distributor for all costs in connection with obtaining, holding and maintaining CFDA Registration Certificates for the Products, subject to a ceiling of $250,000, including inspection and test fee for the Product and registration application fee(collectively, the “CFDA Registration Fee”).
 15.05   In the event this Agreement is terminated by Company in accordance with Section 15.01(i), Company shall agree and acknowledge that Distributor or any of its successors may sell its remaining inventory of Products.
 15.06   In the event this Agreement is terminated in accordance with Section 15.01(iv), then to the extent it is physically or legally possible, Distributor may, at its sole option, retain the right to sell its remaining inventory of Products. Company shall also reimburse Distributor for the CFDA Registration Fee.
 15.07   In the event this Agreement is terminated in accordance with Section 15.01, the Distributor shall not accept any new purchase orders from its customers and shall cease to use the Trademarks and any other intellectual property which belongs to the Company.
 15.08   Notwithstanding anything to the contrary in this Agreement, the above Section 15.07 shall not apply if Distributor or any of its successors retains the right to sell its remaining inventory of Products in accordance with Section 15.02 through Section 15.06 hereof.
 15.09   The provisions of Article 9 through Article 17 and any other provisions hereof which by the intent, nature or meaning thereof have validity beyond the termination shall survive the termination of this Agreement for any reason.  All other rights and obligations of the Parties shall cease upon termination of this Agreement.
 14
  
  
  
 ARTICLE 16
FORCE MAJEURE
 16.01   The time for performance of a Party impacted by a Force Majeure Event, other than the satisfaction of payment obligations that have accrued under this Agreement, is excused, without liability, for the duration of time that the Force Majeure Event impairs such Party’s ability to perform its obligations under this Agreement.
 16.02   The Party whose performance is affected by a Force Majeure Event (the “Affected Party”) shall give prompt written notice to the other Party stating the details and expected duration of the event.  Once notice is given of a Force Majeure Event, the Parties shall keep each other reasonably informed of the situation until the Affected Party’s performance is no longer affected by the Force Majeure Event or this Agreement is terminated, whichever occurs first.  If the performance of the Affected Party does not resume within ninety (90) days of the occurrence of a Force Majeure Event, the other Party shall have the right to terminate this Agreement without penalty, except Distributor’s satisfaction of payment obligations that have accrued under this Agreement shall survive the termination of this Agreement.  Each Party has full management discretion in dealing with its own labor issues.
 ARTICLE 17
MISCELLANEOUS
 17.01   This Agreement shall be governed by and construed under the laws of People’s Republic of China, without reference to its conflicts of law principles.  The United Nations Conventions on Contracts for the International Sale of Goods shall not be applicable to this Agreement. Any dispute, controversy, difference or claim arising out of or relating to this Agreement, including the existence, validity, interpretation, performance, breach or termination thereof or any dispute regarding non-contractual obligations arising out of or relating to it shall be settled through friendly negotiations.  In case no settlement can be reached through such negotiations within forty-five (45) days of the commencement thereof, any such dispute, controversy, difference or claim shall be referred to and finally resolved by arbitration administered by the Hong Kong International Arbitration Centre (“HKIAC”) under the HKIAC Administered Arbitration Rules in force when the notice of arbitration is submitted.  The seat of arbitration shall be Hong Kong and the number of arbitrators shall be three and the arbitration proceedings shall be conducted in English.
 17.02   This Agreement may not be assigned or otherwise transferred, nor may any right or obligation hereunder be assigned or transferred, by either Party without the prior, written consent of the other Party.  Notwithstanding the foregoing, either Party may, with the other Party’s consent, assign this Agreement and its rights and obligations hereunder in whole or in part to an Affiliate.  The assigning Party shall remain responsible for the performance by its assignee of this Agreement or any obligations hereunder so assigned to such assignee.
 15
  
  
  
 17.03   This Agreement and the Exhibits referred to in this Agreement between the Parties, together with the Technology Licensing and Manufacturing Agreement, Component Manufacturing Agreement and the Brazil Registration and Distribution Agreement constitute the entire agreement between the Parties with respect to the subject matter hereof and supersede all previous arrangements with respect to the subject matter hereof, whether written or oral.  Any amendment or modification to this Agreement shall be made in writing signed by both Parties.
 17.04   Any consent, notice or report required or permitted to be given or made under this Agreement by one of the Parties hereto to the other shall be in writing and (a) delivered by hand, (b) sent by internationally recognized delivery service, (c) sent by registered or certified mail, return receipt requested, postage prepaid, or (d) sent by facsimile transmission confirmed by prepaid, registered or certified mail letter, and shall be deemed to have been properly served to the addressee upon receipt of such written communication, in any event to the following addresses:
 If to the Company:      LOMBARD MEDICAL LIMITED
888 Prospect Street #200
La Jolla, CA 92037
Attention: Bill Kulback
Email: bill.kullback@lombardmedical.com 
  
 If to the Distributor:    MICROPORT ENDOVASCULAR (SHANGHAI) CO., LTD.
Building #1, 3399 Kangxin Rd., SIMZ Century Medicine Park Shanghai 201318, P. R. China
Attention: Tracy Xi
Email: mpendo@microport.com
Facsimile No.: 86-21 33750026
 Either Party may change its address to which notices shall be sent by giving notice to the other Party in the manner herein provided.
 17.05   Each Party agrees to execute, acknowledge and/or deliver such further instruments, and to do all other acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement.
 17.06   This Agreement has been prepared jointly and shall not be strictly construed against either Party.
 17.07   The captions or headings of the Sections hereof are inserted only as a matter of convenience or for reference and shall have no effect on the meaning of the provisions hereof.
 17.08   No failure on the part of a Party to exercise, and no delay in exercising, any right, power, remedy or privilege under this Agreement, or provided by statute or at law or in equity or otherwise, shall impair, prejudice or constitute a waiver of any such right, power, remedy or privilege or be construed as a waiver of any breach of this Agreement or as an acquiescence therein, nor shall any single or partial exercise of any such right, power, remedy or privilege preclude any other or further exercise thereof or the exercise of any other right, power, remedy or privilege.
 16
  
  
  
 17.09   If any provision hereof should be held invalid, illegal or unenforceable in any respect in any jurisdiction, the Parties hereto shall substitute, by mutual consent, valid provisions for such invalid, illegal or unenforceable provisions, which valid provisions in their economic effect are sufficiently similar to the invalid, illegal or unenforceable provisions that it can be reasonably assumed that the Parties would have entered into this Agreement with such valid provisions.  In case such valid provisions cannot be agreed upon, the invalidity, illegality or unenforceability of one or several provisions of this Agreement shall not affect the validity of this Agreement as a whole, unless the invalid, illegal or unenforceable provisions are of such essential importance to this Agreement that it is to be reasonably assumed that the Parties would not have entered into this Agreement without the invalid, illegal or unenforceable provisions.
 17.10   This Agreement may be executed in one or more counterparts by the parties, which may be by facsimile signature, email or PDF, each of which when executed and delivered, by facsimile transmission, email or PDF, will be an original and all of which will constitute but one and the same Agreement.
 17.11   In the event any term of this Agreement is inconsistent with the terms of Purchase Order issued by Distributor, then the terms of this Agreement shall control.
 17.12   Except where the context expressly requires otherwise, (a) the use of any gender herein shall be deemed to encompass references to either or both genders, and the use of the singular shall be deemed to include the plural (and vice versa); (b) the words “include”, “includes” and “including” shall be deemed to be followed by the phrase “without limitation” and shall not be interpreted to limit the provision to which it relates; (c) the word “will” shall be construed to have the same meaning and effect as the word “shall”; (d) any definition of or reference to any agreement, instrument or other document herein shall be construed as referring to such agreement, instrument or other document as from time to time amended, supplemented or otherwise modified; (e) any reference in this Agreement to any Person shall be construed to include the Person’s successors and assigns; (f) the words “herein”, “hereof” and “hereunder”, and words of similar import, shall be construed to refer to this Agreement, and not to any particular provision of this Agreement; (g) all references herein to Sections or Exhibits shall be construed to refer to Sections or Exhibits of this Agreement; (h) the word “notice” means notice in writing (whether or not specifically stated); (i) provisions that require that a Party, the Parties “agree,” “consent” or “approve” or the like shall require that such agreement, consent or approval be specific and in writing, whether by written agreement, letter, approved minutes or otherwise (but excluding e-mail and instant messaging); (j) references to any specific law, rule or regulation, or article, section or other division thereof, shall be deemed to include the then-current amendments thereto or any replacement or successor law, rule or regulation thereof.
 (Signature page follows)

  17
  
  
  
 IN WITNESS WHEREOF, the Parties to the Agreement by their duly authorized representatives have executed this Agreement as of the date first written above.
 	 LOMBARD MEDICAL LIMITED
	 MICROPORTENDOVASCULAR (SHANGHAI) CO., LTD.

	 By: 
	 By: 

	 Title: 
	 Title:

 [The remainder of this page intentionally left blank]

 18
  
  
  
  
 Exhibit A
 The Products included in this Agreement are:
 1.         AorfixTM
 AorfixTM AAA Flexible Stent Graft System with IntelliFlexTM Low Profile Delivery System.
 2.         AlturaTM
 AlturaTM Endograft System
 
 19

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00270-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00270-of-00352.parquet"}]]